Correlation Between NewAmsterdam Pharma and Phio Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NewAmsterdam Pharma and Phio Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NewAmsterdam Pharma and Phio Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NewAmsterdam Pharma and Phio Pharmaceuticals Corp, you can compare the effects of market volatilities on NewAmsterdam Pharma and Phio Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NewAmsterdam Pharma with a short position of Phio Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of NewAmsterdam Pharma and Phio Pharmaceuticals.

Diversification Opportunities for NewAmsterdam Pharma and Phio Pharmaceuticals

0.17
  Correlation Coefficient

Average diversification

The 3 months correlation between NewAmsterdam and Phio is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding NewAmsterdam Pharma and Phio Pharmaceuticals Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Phio Pharmaceuticals Corp and NewAmsterdam Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NewAmsterdam Pharma are associated (or correlated) with Phio Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Phio Pharmaceuticals Corp has no effect on the direction of NewAmsterdam Pharma i.e., NewAmsterdam Pharma and Phio Pharmaceuticals go up and down completely randomly.

Pair Corralation between NewAmsterdam Pharma and Phio Pharmaceuticals

Given the investment horizon of 90 days NewAmsterdam Pharma is expected to under-perform the Phio Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, NewAmsterdam Pharma is 12.74 times less risky than Phio Pharmaceuticals. The stock trades about -0.07 of its potential returns per unit of risk. The Phio Pharmaceuticals Corp is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  190.00  in Phio Pharmaceuticals Corp on December 30, 2024 and sell it today you would lose (61.00) from holding Phio Pharmaceuticals Corp or give up 32.11% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

NewAmsterdam Pharma  vs.  Phio Pharmaceuticals Corp

 Performance 
       Timeline  
NewAmsterdam Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Phio Pharmaceuticals Corp 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Phio Pharmaceuticals Corp are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Phio Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

NewAmsterdam Pharma and Phio Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NewAmsterdam Pharma and Phio Pharmaceuticals

The main advantage of trading using opposite NewAmsterdam Pharma and Phio Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NewAmsterdam Pharma position performs unexpectedly, Phio Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will offset losses from the drop in Phio Pharmaceuticals' long position.
The idea behind NewAmsterdam Pharma and Phio Pharmaceuticals Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities